EUVIMEDEUVIMED entdecken
Open Access

High-risk features associated with recurrence in stage I lung adenocarcinoma

Cameron N Fick, Elizabeth G Dunne, Stijn Vanstraelen, Nicolas Toumbacaris, Kay See Tan, Gaetano Rocco, Daniela Molena, James Huang, Bernard J Park, Natasha Rekhtman, William D Travis, Jamie E Chaft und 6 weitere

The Journal of Thoracic and Cardiovascular Surgery · 2025-02 · 169 (2) · 436-444.e6

DOI: 10.1016/j.jtcvs.2024.05.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2025-02. Verfasst von Cameron N Fick und 17 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung, Neoplasm Recurrence, Local, Pneumonectomy. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: There is a lack of knowledge regarding the use of prognostic features in stage I lung adenocarcinoma (LUAD). Thus, we investigated clinicopathologic features associated with recurrence after complete resection for stage I LUAD. METHODS: We performed a retrospective analysis of patients with pathologic stage I LUAD who underwent R0 resection from 2010 to 2020. Exclusion criteria included history of lung cancer, induction or adjuvant therapy, noninvasive or mucinous LUAD, and death within 90 days of surgery. Fine and Gray competing-risk regression assessed associations between clinicopathologic features and disease recurrence. RESULTS: In total, 1912 patients met inclusion criteria. Most patients (1565 [82%]) had stage IA LUAD, and 250 developed recurrence: 141 (56%) distant and 109 (44%) locoregional only. The 5-year cumulative incidence of recurrence was 12% (95% CI, 11%-14%). Higher maximum standardized uptake value of the primary tumor (hazard ratio [HR], 1.04), sublobar resection (HR, 2.04), higher International Association for the Study of Lung Cancer grade (HR, 5.32 [grade 2]; HR, 7.93 [grade 3]), lymphovascular invasion (HR, 1.70), visceral pleural invasion (HR, 1.54), and tumor size (HR, 1.30) were independently associated with a hazard of recurrence. Tumors with 3 to 4 high-risk features had a higher cumulative incidence of recurrence at 5 years than tumors without these features (30% vs 4%; P < .001). CONCLUSIONS: Recurrence after resection for stage I LUAD remains an issue for select patients. Commonly reported clinicopathologic features can be used to define patients at high risk of recurrence and should be considered when assessing the prognosis of patients with stage I disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAdenocarcinoma of LungNeoplasm Recurrence, LocalPneumonectomyHumansMaleFemaleRetrospective StudiesNeoplasm StagingMiddle AgedAgedRisk FactorsRisk AssessmentTime FactorsNeoplasm Invasiveness

Stichwörter der Autor:innen

IASLC gradeSUVmaxhigh risklymphovascular invasionrecurrencestage I lung adenocarcinomavisceral pleural invasion

Autor:innen und Institutionen

  • Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY.
  • Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: jon…

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Fick, C. N., Dunne, E. G., Vanstraelen, S., Toumbacaris, N., Tan, K. S., Rocco, G., Molena, D., Huang, J., Park, B. J., Rekhtman, N., Travis, W. D., Chaft, J. E., Bott, M. J., Rusch, V. W., Adusumilli, P. S., Sihag, S., Isbell, J. M., & Jones, D. R. (2025). High-risk features associated with recurrence in stage I lung adenocarcinoma. The Journal of Thoracic and Cardiovascular Surgery, 169(2), 436-444.e6. https://doi.org/10.1016/j.jtcvs.2024.05.009

Vancouver

Fick CN, Dunne EG, Vanstraelen S, Toumbacaris N, Tan KS, Rocco G, et al. High-risk features associated with recurrence in stage I lung adenocarcinoma. The Journal of Thoracic and Cardiovascular Surgery. 2025;169(2):436-444.e6. doi:10.1016/j.jtcvs.2024.05.009

BibTeX
@article{Fick2025,
  author = {Fick, Cameron N and Dunne, Elizabeth G and Vanstraelen, Stijn and Toumbacaris, Nicolas and Tan, Kay See and Rocco, Gaetano and Molena, Daniela and Huang, James and Park, Bernard J and Rekhtman, Natasha and Travis, William D and Chaft, Jamie E and Bott, Matthew J and Rusch, Valerie W and Adusumilli, Prasad S and Sihag, Smita and Isbell, James M and Jones, David R},
  title = {High-risk features associated with recurrence in stage I lung adenocarcinoma},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2025},
  volume = {169},
  number = {2},
  pages = {436--444.e6},
  doi = {10.1016/j.jtcvs.2024.05.009}
}
Kostenlos starten →